2:44 PM
 | 
Oct 04, 2018
 |  BC Innovations  |  Emerging Company Profile

Banking on exosomes

How Alxerion is mining its biobank of exosomes for cancer discovery

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer.

The company aims to collect and screen 350,000 samples from 30,000 species encompassing a wide range of symbiotic and competing life forms. Exosomes from natural competitors could contain agents with antibiotic, antifungal, antiproliferative or anti-inflammatory properties.

“The pharmaceutical industry strayed away from new drug discovery from naturally occurring molecules,” Steven Hite, Alxerion’s COO, told BioCentury. “Without it, there isn’t a comprehensive path to new exosome and other vesicle drugs, or delivery system discovery.”

Alxerion is using the biobank to develop libraries of exosomes and the nucleic acids, metabolites and aptamers they carry as cargo. It then uses an in silico discovery platform to screen them against targets of interest.

“If you...

Read the full 660 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >